FGFR2 and intrahepatic cholangiocarcinoma: ,14 Novel agents are being tested in clinical trials; for example, the highly selective FGFR2 inhibitor RLY-4008 in a clinical trial of patients with intrahepatic cholangiocarcinoma (and other advanced solid tumors) and FGFR2 alterations (NCT04526106).